Enasidenib mesylate
| Enasidenib mesylate | |
|---|---|
| Term | Enasidenib mesylate |
| Short definition | enasidenib mesylate (EH-nuh-SIH-deh-nib MEH-zih-layt) A drug used to treat adults with acute myeloid leukemia that has come back or has not improved with other treatments . It is used in patients whose cancer has a mutation (change) in the IDH2 gene. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
enasidenib mesylate - (pronounced) (EH-nuh-SIH-deh-nib MEH-zih-layt) A drug used to treat adults with acute myeloid leukemia that has come back or has not improved with other treatments . It is used in patients whose cancer has a mutation (change) in the IDH2 gene. It is also being studied in the treatment of other types of cancer. Enasidenib mesylate blocks the protein IDH2Gen produced by the mutation. Blocking this protein can help prevent cancer cells from growing. Enasidenib mesylate is a type of enzyme inhibitor. Also called Idhifa
External links
- Medical encyclopedia article on Enasidenib mesylate
- Wikipedia's article - Enasidenib mesylate
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski